[8]Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. [9]Plutzky J, e...
25. Wadden, T.A., et al., Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 2021. 325(14): p. 1403-1413. ...
Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: a secondary analysis of the SELECT trial. Presented at: European Congress on Obesity. May 13, 2025. Malaga, Spain. 诺和...
本次 ECO 2025 大会公布了一项重要研究——「Early Clinical Benefit of Semaglutide in Adults with Overweight or Obesity and Cardiovascular Disease:A Secondary Analysis of the SELECT Trial(司美格鲁肽[减重版]在超重或肥胖和心血管疾病成人中的早期临床获益:SELECT 试验的二次分析)」,研究再次揭示了使用司美格...
Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses. At the ADA 84th Scientific Sessions, new data from the SELECT (NCT03574597) trial shows semaglutide’s effect on glycemia, inflammation, and heart failure, demonstrating...
Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the select trialdoi:10.1016/j.atherosclerosis.2024.118518Jorge PlutzkyBrigham and Women's Hospital, Harvard Medical School, Boston, United States of AmericaPawe Bogdański...
SELECT will be the first clinical trial designed to explore the superiority of a long-acting, weekly GLP-1 RA (semaglutide 2.4 mg) versus placebo for reduction of cardiovascular events in patients with established CVD and overweight or obesity but without established type 2 diabetes. Both ...
Already shown to help people shed body weight, semaglutide 2.4 mg (Wegovy; Novo Nordisk) also cuts the risk of major adverse cardiovascular events in adults with overweight or obesity, according to top-line results of the SELECT trial released Tuesday. On top of standard care, the treatment—...
Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints:Semaglutide 2.4 mg reduced the risk of… ...
20. Rubino, D., et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021. 325(14): p. 1414-1425. 21. Ridker, P.M., et al., Antiinflammatory Therapy with Ca...